*To the Editor*: We read with great interest the article by Mathieu \[[@CR1]\], which discusses whether vitamin D is important in diabetes. The author comes to several conclusions. The first is that severe vitamin D deficiency should be avoided in diabetes. We agree that the evidence is compelling. On the role for vitamin D supplementation above the threshold of vitamin D deficiency, it is concluded that high doses of 1,25-dihydroxyvitamin D reduce the incidence of diabetes in primary prevention studies in animal models. From this the author goes on to argue that carefully designed prospective placebo-controlled and randomised trials are required to provide definite answers as to the sense and non-sense of vitamin D supplementation in individuals affected by or at risk of type 1 and type 2 diabetes.

We completely agree: such trials are urgently needed, not only because science has already posed the question, but also because more and more people are actually supplementing themselves and their children on the basis of currently unjustified messages in the lay press.

The author mentions hypercalcaemia, hypercalciuria and kidney stones as potential adverse consequences of injudicious vitamin D supplementation. At this point we would like to add one other potentially even more important concern regarding the injudicious use of vitamin D supplementation. It is well known that even mild prolonged increases in plasma calcium and plasma phosphate concentrations adversely affect the process of atherosclerotic calcification to an appreciable extent \[[@CR2], [@CR3]\]. Such changes could easily occur in response to vitamin D supplementation, increasing the already greater known risk of atherosclerotic vascular events in patients with diabetes and in persons at increased risk of developing diabetes \[[@CR4], [@CR5]\]. It would therefore be highly relevant if future clinical trials on vitamin D supplementation were to include assessment of surrogate markers of atherosclerosis, measures of arterial calcification and assessment of cardiovascular events.
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